Clinical trial · Interventional
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
NCT06807502CI-TRIAL-00109452PROBE-CTCrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Early Stage Breast Cancer (Stage 1-3) | — | UNRESOLVED | — |
| Breast Cancer Invasive | — | UNRESOLVED | — |
| Breast Cancer, Metastatic | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The DM/DIV ScreenCell is the experimental product studied during this research | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Healthy Donor
- description
- Participants with no prior history of cancer and confirmed to be cancer-free at the time of inclusion, as evidenced by a negative mammogram performed within two years before enrollment
- interventionNames
- Device: The DM/DIV ScreenCell is the experimental product studied during this research
- type
- EXPERIMENTAL
- label
- Metastatic
- description
- Participants with metastatic breast cancer or metastatic relapse of previously treated breast cancer with change of therapeutic line at the time of study inclusion, confirmed by a POSITIVE PET-Scan
- interventionNames
- Device: The DM/DIV ScreenCell is the experimental product studied during this research
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening
References
Publications (0)
Data not yet available
No reference posted for this study.